AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. Sells 4,060 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 4,060 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the completion of the sale, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AngioDynamics Stock Down 2.7 %

AngioDynamics stock traded down $0.34 during mid-day trading on Friday, reaching $12.43. The company had a trading volume of 551,541 shares, compared to its average volume of 1,233,167. The company has a 50 day moving average of $8.65 and a 200-day moving average of $7.60. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.13. The firm has a market cap of $503.04 million, a price-to-earnings ratio of -2.21 and a beta of 0.59.

AngioDynamics (NASDAQ:ANGO) last posted its earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business had revenue of $72.90 million for the quarter, compared to analysts’ expectations of $70.93 million. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. The firm’s revenue for the quarter was down .1% on a year-over-year basis. On average, analysts predict that AngioDynamics, Inc. will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of AngioDynamics by 21.3% during the 4th quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 2,832 shares during the period. Moody National Bank Trust Division raised its holdings in shares of AngioDynamics by 70.2% in the fourth quarter. Moody National Bank Trust Division now owns 55,780 shares of the medical instruments supplier’s stock valued at $511,000 after purchasing an additional 23,003 shares during the last quarter. JPMorgan Chase & Co. lifted its position in AngioDynamics by 28.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 553,161 shares of the medical instruments supplier’s stock worth $4,304,000 after buying an additional 123,271 shares in the last quarter. Barclays PLC boosted its holdings in shares of AngioDynamics by 81.0% in the 3rd quarter. Barclays PLC now owns 83,582 shares of the medical instruments supplier’s stock valued at $651,000 after buying an additional 37,394 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in AngioDynamics by 5.1% during the third quarter. Geode Capital Management LLC now owns 960,767 shares of the medical instruments supplier’s stock worth $7,477,000 after purchasing an additional 46,409 shares during the period. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. HC Wainwright boosted their target price on shares of AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Canaccord Genuity Group reduced their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, October 4th.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.